 Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome: Findings from the Montalcino Aortic Consortium  Brief title: Arterial Events Associated with Aortopathy Genes   Ernesto Calderon-Martinez, MD*,a Walter V. Velasco, MD*,a Dongchuan Guo, PhD*,a Ellen H. Hostetler, BA,a Zhang Xun, MD, PhD,a Sara Stephens, PhD,b Sherene Shalhub, MD,c Julie De Backer, MD, PhD,d Maral Ouzounian, MD, PhD,e Scott A. LeMaire, MD,f  Oiliver Milleron, MD,g Nadine Hanna, MD,h Pauline Arnaud, Pharm D, PhD,h Maria Tchitchinadze, MD,i Siddhart K. Prakash, MD,a Mark Lindsay, MD, PhD,j Julien Marcadier, MD,k Richmond Jeremy, MD, PhD,l Shaine A. Morris, MD, MPH,b Anji T. Yetman, MD,m Catherine Boileau, PhD,n Alan C. Braverman, MD,o Guillaume Jondeau, MD, PhDc ‡, Dianna M. Milewicz, MD, PhDa ‡ Affiliations: aDivision of Medical Genetics, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. bDivision of Cardiology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. cDivision of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health Science University, Portland, OR, USA. dDepartment of Cardiology and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium ;Centre National de Reference pour le Syndrome de Marfan et les Syndromes Apparentés, VASCERN HTAD European Reference Centre, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France.  eDivision of Cardiovascular Surgery, Department of Surgery, University of Toronto, Toronto General Hospital, Toronto, Canada. fDivision of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA; Texas Heart Institute, Houston, TX, USA. g Université de Paris, LVTS, INSERM U1148, Hôpital Bichat-Claude-Bernard, Paris, France; Centre National de Reference pour le Syndrome de Marfan et les Syndromes Apparentés, VASCERN HTAD European Reference Centre, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France. ;Service de Cardiologie, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France. hUniversité de Paris, LVTS, INSERM U1148, Hôpital Bichat-Claude-Bernard, Paris, France; Centre National de Reference pour le Syndrome de Marfan et les Syndromes Apparentés, VASCERN HTAD European Reference Centre, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France. ;Département de Génétique, AP-HP, Hôpital Bichat-Claude-Bernard, Paris, France. i Centre National de Reference pour le Syndrome de Marfan et les Syndromes Apparentés, VASCERN HTAD European Reference Centre jCardiovascular Genetics Program, Massachusetts General Hospital, Boston, MA, USA; Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. kDepartment of Medical Genetics, Alberta Children's Hospital, Calgary, AB, Canada. lCentral Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Marfan and Aortic Disease Service, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 

mDivision of Pediatric Cardiology, Children's Hospital & Medical Center, University of Nebraska Medical Center, Omaha, NE, USA. nGenetics Department, Hôpital Bichat, Université Paris Cité, Paris, France. oCardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. *These authors share the first authorship. ‡These authors share co-last authorship Corresponding Author: Dianna M. Milewicz, MD PhD, McGovern Medical School, UTHealth, Houston, TX 77030 (DianNC.M.Milewicz@uth.tmc.edu)    METHODS Study Population Institutional Review Boards at institutions participating in this study obtained informed consent and authorization to use deidentified clinical data from all study participants for research. Genotype and clinical data from cohorts of patients and their relatives with rare variants in COL3A1, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3 and FBN1 were combined for these aNAlyses. Patient recruitment, data collection, and sites were previously described. 1,2  Demographic and clinical data were abstracted from medical records and entered into a Research Electronic Data Capture database. Clinical data included history of arterial or aortic event, including age at first event and number of total events. The primary outcome was arterial event, defined as arterial dissection, rupture, or aneurysm requiring surgical repair. Aortic events, defined as aortic dissection, rupture, or aneurysm requiring surgical repair, were also assessed as previously reported.3 Cases with neoNAtal or infantile MFS were excluded due to the cardiac complications associated with this condition.4–6 Rare variants in genes listed above were curated as to their pathogenicity based on the American College of Medical Genetics- Association for Molecular Pathology guidelines (accessed April 2018),7 and recently modified by the ClinGen General Sequence Variant Curation Process Standard Operating Procedure v3.2.8  FunctioNAl effects of genetic variants were categorized as missense variant, haploinsufficiency, in-frame insertion or deletion or variants that leads to premature truncation of translation but not nonsense-mediated decay of the transcript.   Statistical Analysis The cohort was first stratified by affected gene and characteristics were described. Differences in characteristics by gene were evaluated using Fisher’s exact and chi-square for categorical variables and Kruskal-Wallis test for continuous variables. Chi-square test was used to examine differences in frequency of arterial and aortic events by gene. Arterial events at any time including event type, median age, sex distribution, and distribution of variant types. Kaplan-Meier (KM) curves were used to visualize time to first arterial event in the overall cohort and stratified by gene among all subjects, as well as curves for aortic events and arterial events agains aortic events with log-rank test denoting differences between curves. Subjects with PVs in TGFB3 were not included due to low event counts in the arterial events curves, and TGFB3 for the aortic events curves. KM and log-rank analyses were repeated to assess time to arterial event by individual genes with COL3A1 (given COL3A1 having the highest frequency of arterial events in the cohort). KM and log-rank analyses were further stratified by sex to assess for differences in 

1) all genes 2) each gene with COL3A1 as the referent among males and females separately 3) Same gene among males and females.  Arteries were classified into five zones based on their location: head and neck, thorax, abdomen/pelvis, upper extremities, and lower extremities. To indicate the frequency of artery involvement, heatmaps were generated for each region. The head and neck zone included the cerebral, internall carotid, common carotid, vertebral, and subclavian arteries. The upper extremities zone encompassed the axillary and brachial arteries, while the thorax zone included the coronary, right pulmonary artery, and internal mammary arteries. The abdominopelvic zone comprised the celiac, splenic, superior mesenteric, hepatic, renal, common iliac, internal iliac, and external iliac arteries. Finally, the lower extremities zone included the femoral and popliteal arteries. These classifications provided a framework for visualizing arterial involvement across different regions. Log-binomial analyses were used to evaluate for risk of arterial and aortic events by systemic features and cardiovascular risk factors. A total of 62 phenotypic features and systemic risk factors were set up in the RedCap database for this analysis, patients from the French population did not collect all these features or were collected differently. Risk factors with fewer than six reported features were excluded from the analysis to ensure sufficient sample size and the stability of the estimates. Additionally, risk factors with relative risk (RR) values or confidence intervals (CI) falling outside the predefined range of 0.01 to 100 were excluded from the results to maintain a focus on plausible associations. These thresholds were implemented to minimize the influence of rare events and extreme statistical values, which could reflect data sparsity or overfitting. Finally, incidence rates (IRs) of aortic and arterial events per 100 person-years were computed by gene. Incidence rate ratios (IRRs) were generated and statistically compared by gene using subjects with COL3A1 and TGFBR2 variants as the referent for aNAlysis of arterial and aortic events, respectively. A two-sided p-value <0.05 was considered statistically significant. Statistical analyses were performed using R studio version 4.3.2.	   References:  1. Jondeau G, Ropers J, Regalado E, et al. InterNAtioNAl Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the Montalcino Aortic Consortium. Circ Cardiovasc Genet. 2016;9:548. 2. Hostetler EM, Regalado ES, Guo DC, et al. SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium. J Med Genet. 2019;56:252–260. 3. Regalado ES, Morris SA, Braverman AC, et al. Comparative Risks of Initial Aortic Events Associated With Genetic Thoracic Aortic Disease. J Am Coll Cardiol. 2022;80:857–869. 4. Soma K, Kitagawa Y, Toki T, et al. Early-onset Marfan syndrome with a novel missense mutation: A case report. J Cardiol Cases. 2023;27:283–286. 5. Ozyurt A, Baykan A, Argun M, et al. Early onset marfan syndrome: Atypical clinical presentation of two cases. Balkan J Med Genet. 2015;18:71. 6. ArdhaNAri M, Barbouth D, SwamiNAthan S. Early-Onset Marfan Syndrome: A Case Series. J Pediatr Genet. 2019;8:86. 

7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424. 8. ClinGen Variant Curation SOP Committee. ClinGen General Sequence Variant Curation Process Standard Operating Procedure v3.2. https://clinicalgenome.org/site/assets/files/7438/variant_curation_sop_v3_2_oct_2022.pdf. 2022.                                             

Supplemental table 1: Study population and pathogenic and likely pathogenic variants in genes, without French cohort.  TOTAL (n=616) COL3A1 (n = 124) TGFBR1 (n=81) TGFBR2 (n=109) SMAD3 (n= 117) TGFB2 (n=103) TGFB3 (n=30) FBN1 (n=52) No of Probands 346 (56.2%) 100 (80.6%) 48 (59.3%) 58 (53.2%) 50 (42.7%) 42 (40.8%) 20 (66.7%) 28  (53.8%) <18y 113 (18.3%) 21 (16.9%) 17 (21.0%) 23 (21.1%) 10 (8.5%) 26 (25.2%) 9 (30.0%) 7 (13.5%) Type of variant Missense 409 (66%) 80 (64%) 80 (99%) 96 (88%) 69 (59%) 47 (46%) 7 (37.7%) 30 (58%) Haploinsufficiency 141 (23%) 15 (12%) 1 (1%) 1 (1%) 30 (26%) 56 (54%) 23 (77%) 15 (29%) Inframe Indel 42 (7%) 25 (20%) 0 (0%) 1 (1%) 9 (8%) 0 (0.0%) 0 (0.0%) 6 (11%) PTC nonNMD 12 (2%) 2 (2%) 0 (0%) 6 (5%) 4 (3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Other/ Unknown 12 (2%) 2 (2%) 0 (0.0%) 5 (5%) 5 (4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Ethnicity Hispanic/ Latino 46 (7%) 8 (6%) 3 (4%) 8 (7%) 10 (8%) 14 (14%) 1 (3%) 2 (4%) Not Hispanic/ Latino 535 (87%) 110 (89%) 72 (89%) 91 (84%) 98 (84%) 89 (86%) 29 (97%) 46 (88%) Unknown 35 (6%) 6 (5%) 6 (7%) 10 (9%) 9 (7%) 0 (0%) 0 (0%) 4 (8%) Race American Indian or Alaska Native 5 (1%) 3 (2%) 0 (0%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Asian 9 (1%) 2 (2%) 0 (0%) 2 (2%) 2 (2%) 2 (2%) 0 (0%) 1 (2%) Black 20 (3%) 1 (1%) 0 (0%) 1 (1%) 7 (6%) 3 (3%) 4 (13%) 4  (8%) White 539 (88%) 109 (88%) 78 (96%) 95 (87%) 96 (82%) 94 (91%) 26 (87%) 41 (79%) Other/ Unknown 43 (7%) 9 (7%) 3 (4%) 9 (8%) 12 (10%) 4 (4%) 0 (0%) 6 (11%) Sex Male 294 (48%) 55 (44%) 37 (46%) 54 (49%) 52 (44%) 58 (56%) 15 (50%) 23 (44%) Female 322 (52%) 69 (56%) 44 (54%) 55 (51%) 65 (56%) 45 (44%) 15 (50%) 29 (56%) Location of recruitment Australia 60 (10%) 7 (6%) 14 (17%) 9 (8%) 27 (23%) 1 (1%) 1 (3%) 1 (2%) Belgium 18 (3%) 1 (1%) 2 (3%) 5 (5%) 5 (4%) 2 (2%) 3 (10%) 0 (0%) Canada 28 (5%) 5 (4%) 5 (6%) 4 (4%) 8 (7%) 0 (0%) 4 (14%) 2  (4)% UK 34 (5%) 8 (6%) 6 (7%) 10 (9%) 7 (6%) 2 (2%) 1 (3%) 0 (0%) US 476 (77%) 103 (83%) 54 (67%) 81 (74%) 70 (60%) 98 (95%) 21 (70%) 49 (94%)  PTC non NMD: Premature Termination Codon non-Nonsense-Mediated Decay   Supplemental table 2: Number of arterial and aortic events by gene and proband status.  TOTAL  (n=1790) COL3A1 (n = 125) TGFBR1 (n=137) TGFBR2 (n=168) SMAD3 (n= 196) TGFB2 (n=126) FBN1 (n=1028) Arterial events  93  30 13  13  13  8   16  Arterial Events in relatives 71 (76.3%) 26 (86.7%) 11 (84.6%) 10 (77%) 7 (53.8%) 4 (50.0%) 13 (81.3%) Arterial Events in probands 22 (23.7%) 4 (13.3%) 2 (15.4%) 3 (23%) 6 (46.2%) 4 (50.0%) 3 (18.7%) Aortic events 496  32  52  72  66  38  236  Aortic Events in probands 350 (70.6%) 28 (87.5%) 42 (80.8%) 46 (63.9%) 42 (63.6%) 24 (63.2%) 168 (71.2%) Aortic events in relatives 146 (29.4%) 4 (12.5%) 10 (19.2%) 26 (36.1%) 24 (36.4%) 14 (36.8%) 68 (28.8%)     

 
Supplemental Table 3. Age at last follow-up, and distribution of events by age  TOTAL  (n=1790) COL3A1 (n = 125) TGFBR1 (n=137) TGFBR2 (n=168) SMAD3 (n= 196) TGFB2 (n=126) FBN1 (n=1028) Arterial Events Arterial events TOTAL (n = 93) COL3A1 (n = 30) TGFBR1 (n=13) TGFBR2 (n=13) SMAD3 (n= 13) TGFB2 (n=8) FBN1 (n=16) Median age at arterial event, KM est. for entire cohort NA 73.1 (64 – NA) NA NA 84.5 (84.5 – NA) NA NA 
N and KM est. for Arterial event by age 20 40 60 80 100 
  5 (0.3%) 48 (5.2%) 32 (13.4%) 7 (18.8%) 1 (45.8%) 
  3 (2.8%) 19 (22.9%) 5 (33%) 3 (55%) 0 (0.0%) 
  0 (0.0%) 6 (6.8%) 7 (23.4%) 0 (0.0%) 0 (0.0%) 
  1 (0.7%) 6 (7%) 5 (22.2%) 1(27.4%) 0 (0.0%) 
  0 (0.0%) 5 (3.7%) 6 (11.1%) 1 (13.4%) 1 (56.7%) 
  0 (0.0%) 3 (4.1%) 5 (20.2%) 0 (0.0%) 0 (0.0%) 
  1 (0.1%) 9 (2.1%) 4 (5.4%) 2 (8.2%) 0 (0.0%) Aortic Events Aortic Events TOTAL (n = 496) COL3A1 (n = 32) TGFBR1 (n=52) TGFBR2 (n=72) SMAD3 (n= 66) TGFB2 (n=38) FBN1 (n=236) Median age at Aortic event, KM est. for entire cohort 55 (52-58) 65 (57-NA) 51 (47-61) 41 (35 – 57) 56 (52-61) 56 (47-NA) 55 (51-65) 
N and KM est. for Aortic event by age 20 40 60 80 100 
  55 (3.7%) 238 (26.6%) 172 (56.2%) 30 (75.9%) 1 (79.9%) 
  1 (0.8%) 12 (14.8%) 14 (42.4%) 5 (79.1%) 0 (0.0%) 
  11 (9.6%) 11 (22.1%) 25 (62.4%) 4 (78.5%) 1 (89.3%) 
  17 (11.7%) 39 (47.9%) 11 (67.8%) 5 (90.3%) 0 (0.0%) 
  1 (0.5%) 16 (12.6%) 43 (59.5%) 6 (89.9%) 0 (0.0%) 
  0 (0.0%) 17 (21.0%) 17 (53.9%) 4 (74.5%) 0 (0.0%) 
  25 (3.1%) 143 (29.6%) 62 (52.1%) 6 (58.3%) 0 (0.0%) Est.: Estimate; KM: Kaplan Meier; NA= Not available (cannot calculate if 50% of cohort did not have event) All values are listed as n or median (25%,75%)  
 
 
 
Supplemental Table 4. Association between variant type and arterial dissections 

Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 12 4 0.580 Inframe Indel 20 5 Missense 70 10 Others/Unknown 2 0 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 10 0 1 Inframe Indel 6 0 Missense 111 10 TGFBR2 Haploinsufficiency 1 0 1 Inframe Indel 2 0 Missense 142 6 Others/Unknown 5 0 PTC nonNMD 12 0 TGFB2 Haploinsufficiency 69 0 0.089 Missense 54 3 SMAD3 Haploinsufficiency 51 1 0.387 Inframe Indel 12 0 Missense 107 5 Others/Unknown 5 0 PTC nonNMD 13 2 FBN1 Haploinsufficiency 291 2 1 Inframe Indel 128 0 Missense 592 4 PTC nonNMD 11 0 TGFb-pathway genes  Haploinsufficiency 131 1 0.084 Inframe Indel 20 0 Missense 414 24 Others/Unknown 10 0 PTC nonNMD 25 2  NA: Not available to calculate         

Supplemental Table 5. Association between variant type and arterial rupture Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 16 0 0.689 Inframe Indel 23 2 Missense 75 5 Others/Unknown 2 0 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 10 0 NA Inframe Indel 6 0 Missense 121 0 TGFBR2 Haploinsufficiency 1 0 NA Inframe Indel 2 0 Missense 148 0 Others/Unknown 5 0 PTC nonNMD 12 0 TGFB2 Haploinsufficiency 67 2 0.500 Missense 57 0 SMAD3 Haploinsufficiency 51 1 0.674 Inframe Indel 12 0 Missense 111 1 Others/Unknown 5 0 PTC nonNMD 15 0 FBN1 Haploinsufficiency 293 0 NA Inframe Indel 128 0 Missense 596 0 PTC nonNMD 11 0 TGFb-pathway genes Haploinsufficiency 129 3 0.149 Inframe Indel 20 0 Missense 437 1 Others/Unknown 10 0 PTC nonNMD 27 0  NA: Not available to calculate         

Supplemental Table 6. Association between variant type and arterial repair Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 14 2 0.221 Inframe Indel 25 0 Missense 78 2 Others/Unknown 2 0 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 10 0 1 Inframe Indel 6 0 Missense 118 3 TGFBR2 Haploinsufficiency 1 0 0.150 Inframe Indel 1 1 Missense 142 6 Others/Unknown 5 0 PTC nonNMD 12 0 TGFB2 Haploinsufficiency 69 0 0.089 Missense 54 3 SMAD3 Haploinsufficiency 50 2 0.554 Inframe Indel 12 0 Missense 111 1 Others/Unknown 5 0 PTC nonNMD 15 0 FBN1 Haploinsufficiency 289 4 0.437 Inframe Indel 126 2 Missense 592 4 PTC nonNMD 11 0 TGFb-pathway genes Haploinsufficiency 130 2 0.623 Inframe Indel 19 1 Missense 425 13 Others/Unknown 10 0 PTC nonNMD 27 0           

Supplemental Table 7. Association between variant type and aortic dissection type A Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 11 5 <0.01 Inframe Indel 25 0 Missense 77 3 Others/Unknown 2 0 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 9 1 1 Inframe Indel 6 0 Missense 106 15 TGFBR2 Haploinsufficiency 1 0 0.75 Inframe Indel 2 0 Missense 127 21 Others/Unknown 4 1 PTC nonNMD 10 2 TGFB2 Haploinsufficiency 65 4 0.22 Missense 50 7 SMAD3 Haploinsufficiency 44 8 0.58 Inframe Indel 10 2 Missense 96 16 Others/Unknown 3 2 PTC nonNMD 13 2 FBN1 Haploinsufficiency 282 11 0.11 Inframe Indel 124 4 Missense 585 11 PTC nonNMD 10 1 TGFb-pathway genes Haploinsufficiency 119 13 0.36 Inframe Indel 18 2 Missense 379 59 Others/Unknown 7 3 PTC nonNMD 23 4            

Supplemental Table 8. Association between variant type and aortic dissection type B  Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 15 1 0.27 Inframe Indel 24 1 Missense 69 11 Others/Unknown 1 1 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 10 0 1 Inframe Indel 6 0 Missense 120 1 TGFBR2 Haploinsufficiency 1 0 1 Inframe Indel 2 0 Missense 145 3 Others/Unknown 5 0 PTC nonNMD 12 0 TGFB2 Haploinsufficiency 69 0 0.2 Missense 55 2 SMAD3 Haploinsufficiency 50 2 0.32 Inframe Indel 12 0 Missense 109 3 Others/Unknown 5 0 PTC nonNMD 13 2 FBN1 Haploinsufficiency 284 9 0.84 Inframe Indel 126 2 Missense 580 16 PTC nonNMD 11 0 Composite (TGFBR1/TGFBR2/TGFB2/SMAD3) Haploinsufficiency 130 2 0.37 Inframe Indel 20 0 Missense 429 9 Others/Unknown 10 0 PTC nonNMD 25 2        

Supplemental Table 9. Association between variant type and aortic aneurysm repair  Gene Group Type of Variant Events No Events Yes p-value COL3A1 Haploinsufficiency 15 1 1 Inframe Indel 23 2 Missense 73 7 Others/Unknown 2 0 PTC nonNMD 2 0 TGFBR1 Haploinsufficiency 9 1 0.64 Inframe Indel 5 1 Missense 88 33 TGFBR2 Haploinsufficiency 0 1 0.03 Inframe Indel 0 2 Missense 110 38 Others/Unknown 5 0 PTC nonNMD 8 4 TGFB2 Haploinsufficiency 59 10 0.15 Missense 42 15 SMAD3 Haploinsufficiency 46 6 0.07 Inframe Indel 8 4 Missense 98 14 Others/Unknown 5 0 PTC nonNMD 10 5 FBN1 Haploinsufficiency 218 75 <0.01 Inframe Indel 104 24 Missense 516 80 PTC nonNMD 8 3 TGFb-pathway genes Haploinsufficiency 114 18 0.01 Inframe Indel 13 7 Missense 338 100 Others/Unknown 10 0 PTC nonNMD 18 9   
 
 
 
 

Supplemental Table 10. Incidence rate per gene and decade for arterial events  Gene Name Age Events Total Person Years Incidence Rate per 1000 Person Years (100 people living 1 decade) COL3A1 0 0 1222 0 COL3A1 10 5 1087 4.6 COL3A1 20 31 956 32.43 COL3A1 30 9 781 11.52 COL3A1 40 8 493.82 16.2 COL3A1 50 2 264 7.58 COL3A1 60 3 128 23.44 COL3A1 70 1 20 50 FBN1 0 0 9983.25 0 FBN1 10 1 8280.55 0.12 FBN1 20 4 6263.19 0.64 FBN1 30 6 4325.49 1.39 FBN1 40 0 2644.99 0 FBN1 50 6 1363.12 4.4 FBN1 60 2 568.07 3.52 FBN1 70 0 120.41 0 FBN1 80 0 2.34 0 SMAD3 0 0 1934.14 0 SMAD3 10 0 1801.08 0 SMAD3 20 2 1531.06 1.31 SMAD3 30 3 1181.75 2.54 SMAD3 40 3 946.49 3.17 SMAD3 50 4 617.73 6.48 SMAD3 60 1 251.44 3.98 SMAD3 70 1 57.92 17.27 SMAD3 80 4 13 307.69 TGFB2 0 0 1195.05 0 TGFB2 10 0 1025.8 0 TGFB2 20 2 825.62 2.42 TGFB2 30 1 648.15 1.54 TGFB2 40 2 453.1 4.41 TGFB2 50 3 241.27 12.43 TGFB2 60 0 97.35 0 TGFB2 70 0 33.16 0 TGFB2 80 0 8 0 TGFBR1 0 0 1332.15 0 TGFBR1 10 0 1141.89 0 TGFBR1 20 3 915.44 3.28 TGFBR1 30 3 681.78 4.4 TGFBR1 40 7 506.12 13.83 TGFBR1 50 4 326.05 12.27 TGFBR1 60 3 141.66 21.18 TGFBR1 70 0 27.28 0 TGFBR1 80 0 6 0 TGFBR2 0 0 1649.01 0 TGFBR2 10 1 1379.23 0.73 TGFBR2 20 3 1092.09 2.75 TGFBR2 30 8 863.71 9.26 TGFBR2 40 4 513.71 7.79 TGFBR2 50 2 210.71 9.49 TGFBR2 60 2 119.15 16.79 TGFBR2 70 0 37.95 0 TGFBR2 80 0 10 0  Supplemental Table 11. Incidence rate and incidence rate ratio for aortic events Gene Name Events Person Years Incidence Rate (95% CI) IRR (95% CI) p-value COL3A1 59 1931.82 3.05 (2.37-3.94) 1.0 (0.73-1.36) 1 FBN1 19 800.83 2.37 (1.51-3.72) 0.78 (0.48-1.26) 0.31 SMAD3 19 1001.54 1.9 (1.21-2.97) 0.62 (0.38-1.01) 0.05 TGFB2 8 345.83 2.31 (1.16-4.63) 0.76 (0.37-1.55) 0.45 TGFBR1 21 911.29 2.3 (1.5-3.53) 0.75 (0.48-1.2) 0.23  

Supplemental Table 12. Incidence rate per gene and decade for aortic events  Gene Name Decade Events Total Person-Years Incidence Rate COL3A1 0 1 1222 0.82 COL3A1 10 0 1087 0 COL3A1 20 5 956 5.23 COL3A1 30 7 781 8.96 COL3A1 40 9 493.82 18.23 COL3A1 50 5 264 18.94 COL3A1 60 5 128 39.06 COL3A1 70 1 20 50 FBN1 0 0 9983.25 0 FBN1 10 19 8280.55 2.29 FBN1 20 83 6263.19 13.25 FBN1 30 79 4325.49 18.26 FBN1 40 54 2644.99 20.42 FBN1 50 22 1363.12 16.14 FBN1 60 10 568.07 17.6 FBN1 70 0 120.41 0 SMAD3 80 0 2.34 0 SMAD3 0 0 1934.14 0 SMAD3 10 0 1801.08 0 SMAD3 20 7 1531.06 4.57 SMAD3 30 11 1181.75 9.31 SMAD3 40 28 946.49 29.58 SMAD3 50 29 617.73 46.95 SMAD3 60 4 251.44 15.91 SMAD3 70 3 57.92 51.8 TGFB2 80 0 13 0 TGFB2 0 0 1195.05 0 TGFB2 10 0 1025.8 0 TGFB2 20 9 825.62 10.9 TGFB2 30 11 648.15 16.97 TGFB2 40 14 453.1 30.9 TGFB2 50 7 241.27 29.01 TGFB2 60 5 97.35 51.36 TGFB2 70 1 33.16 30.15 TGFBR1 80 0 8 0 TGFBR1 0 0 1332.15 0.75 TGFBR1 10 0 1141.89 9.63 TGFBR1 20 0 915.44 7.65 TGFBR1 30 0 681.78 14.67 TGFBR1 40 0 506.12 37.54 TGFBR1 50 1 326.05 33.74 TGFBR1 60 0 141.66 42.35 TGFBR1 70 0 27.28 0 TGFBR2 80 0 6 333.33 TGFBR2 0 1 1649.01 1.21 TGFBR2 10 11 1379.23 10.88 TGFBR2 20 7 1092.09 20.14 TGFBR2 30 10 863.71 41.68 TGFBR2 40 19 513.71 31.15 TGFBR2 50 11 210.71 9.49 TGFBR2 60 6 119.15 50.36 TGFBR2 70 0 37.95 79.04 TGFBR2 80 2 10 0   Supplemental Table 13. Incidence rate and incidence rate ratio for aortic events  Gene Name Events Person Years Incidence Rate (95% CI) IRR (95% CI) p-value COL3A1 33 1440 2.29 (1.63-3.22) 0.76 (0.52-1.12) 0.16 FBN1 267 9258.44 2.88 (2.56-3.25) 0.96 (0.77-1.18) 0.69 SMAD3 82 3860 2.12 (1.71-2.64) 0.71 (0.53-0.93) 0.01 TGFB2 48 2000 2.4 (1.81-3.18) 0.8 (0.57-1.11) 0.18 TGFBR1 69 2777 2.48 (1.96-3.15) 0.82 (0.61-1.11) 0.2 TGFBR2 102 3386 3.01 (2.48-3.66) Ref Ref 

Supplemental Table 14. Systemic and phenotypic risk factor in COL3A1 participants. Systemic and cardiovascular risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia NA NA NA NA NA NA Atrial fibrillation NA NA NA NA NA NA Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 1.75(0.97-3.16) 0.064 1.04(0.47-2.28) 0.92 2.95(1.25-7.00) 0.014 Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 1.30(0.67-2.55) 0.437 1.14(0.48-2.69) 0.767 1.36(0.46-4.02) 0.574 Phenotypic risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) Risk factor RR (95% CI) p value Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot 2.11(0.83-5.34) 0.117 NA NA NA NA Craniosynostosis NA NA NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA NA NA NA NA NA Digital abnormalities 2.44(1.25-4.77) 0.009 NA NA 1.86(0.54-6.45) 0.327 Dolichocephaly 2.35(0.98-5.65) 0.055 NA NA NA NA Doughy skin texture 2.99(1.55-5.76) 0.001 NA NA 2.84(1.13-7.18) 0.027 Downslanting palpebral fissures NA NA NA NA NA NA Ectopia lentis NA NA NA NA NA NA Emphysema NA NA NA NA NA NA Enophthalmos NA NA NA NA NA NA Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia 0.91(0.43-1.93) 0.803 0.77(0.29-2.07) 0.611 1.02(0.32-3.23) 0.979 High arched palate 3.14(1.61-6.12) 0.001 NA NA NA NA Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA NA NA NA NA NA Hypertelorism* NA NA NA NA NA NA Iridodonesis NA NA NA NA NA NA 

Iris flocculi NA NA NA NA NA NA Joint hypermobility 1.01(0.44-2.35) 0.976 0.58(0.21-1.63) 0.305 1.05(0.27-4.01) 0.943 Kyphosis NA NA NA NA NA NA Livedo reticularis NA NA NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 1.96(0.78-4.96) 0.153 NA NA NA NA Micrognathia NA NA NA NA NA NA Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity NA NA NA NA NA NA Pectus excavatum or chest asymmetry NA NA NA NA NA NA Pes planus 2.86(1.55-5.28) 0.001 NA NA 2.57(0.94-7.07) 0.067 Positive thumb sign NA NA NA NA NA NA Positive wrist sign NA NA NA NA NA NA Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA NA NA NA NA NA Retrognathia NA NA NA NA NA NA Scoliosis NA NA NA NA NA NA Skin hyperextensibility 2.45(1.20-5.01) 0.014 2.78(1.11-6.97) 0.03 1.86(0.54-6.45) 0.327 Skin striae NA NA NA NA NA NA Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax 2.06(0.99-4.32) 0.054 2.03(0.90-4.57) 0.089 NA NA Teeth crowding NA NA NA NA NA NA Thin or transluscent skin* 1.67(0.85-3.26) 0.085 2.09(0.84-5.18) 0.112 1.44(0.55-3.80) 0.459 Tortuosity of intracranial arteries NA NA NA NA NA NA Tortuosity of the aorta NA NA NA NA NA NA Tortuosity of the vertebral or carotid arteries 1.73(0.77-3.85) 0.182 0.88(0.32-2.36) 0.792 NA NA Wide or atrophic scars 2.73(1.54-4.85) <0.001 4.11(1.98-8.57) <0.001 1.43(0.48-4.26) 0.519  *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.        

Supplemental Table 15. Phenotypic and systemic risk factor in TGFb-pathway genes composite  Systemic and cardiovascular risk factors  Overall Male Female Risk Factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia 1.16(0.38-3.49) 0.794 1.13(0.22-5.89) 0.886 1.02(0.16-6.65) 0.979 Atrial fibrillation 1.29(0.53-3.12) 0.569 0.71(0.14-3.70) 0.683 1.61(0.54-4.80) 0.389 Congestive heart failure 1.49(0.41-5.47) 0.546 NA* NA* NA NA Deep vein thrombosis 1.67(0.49-5.71) 0.416 NA NA NA NA Diabetes 2.69(0.78-9.24) 0.116 NA NA 2.19(0.63-7.67) 0.218 Hyperlipidemia NA NA NA NA NA NA Hypertension* 2.44(1.46-4.07) 0.001 2.46(1.03-5.85) 0.043 2.51(1.34-4.72) 0.004 Hyperthyroidism 2.73(0.80-9.38) 0.11 NA NA 1.43(0.23-8.88) 0.698 Idiopathic cardiomyopathy 3.19(1.45-7.03) 0.004 NA* NA* NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 2.62(1.54-4.45) <0.001 4.48(1.89-10.59) 0.001 2.06(0.99-4.26) 0.052 Phenotypic risk factors  Overall Male Female Risk Factor RR (95% CI) p value RR (95% CI) Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA* NA* NA NA NA* NA* Club foot 1.56(0.43-5.73) 0.502 NA NA 1.17(0.18-7.43) 0.868 Craniosynostosis NA* NA* NA NA NA* NA* Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat 0.77(0.11-5.12) 0.783 NA NA NA* NA* Digital abnormalities 1.05(0.40-2.80) 0.916 1.51(0.35-6.42) 0.58 0.90(0.23-3.48) 0.876 Dolichocephaly 0.87(0.33-2.34) 0.788 1.29(0.30-5.61) 0.73 0.75(0.19-2.93) 0.676 Doughy skin texture 2.84(1.59-5.08) <0.001 2.85(0.93-8.71) 0.066 2.77(1.40-5.46) 0.003 Downslanting palpebral fissures 1.47(0.71-3.02) 0.297 1.30(0.38-4.46) 0.677 1.81(0.76-4.33) 0.184 Ectopia lentis NA NA NA NA NA NA Emphysema 1.16(0.18-7.54) 0.874 NA NA NA NA Enophthalmos 1.86(0.73-4.74) 0.195 1.15(0.17-8.03) 0.885 2.43(0.87-6.84) 0.092 Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia* NA* NA* NA* NA* NA* NA* High arched palate 1.56(0.85-2.85) 0.153 1.36(0.46-3.97) 0.576 1.90(0.92-3.94) 0.082 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee 0.84(0.22-3.25) 0.798 1.26(0.18-8.88) 0.817 NA* NA* Hypertelorism* 2.93(1.65-5.18) <0.001 2.64(0.90-7.70) 0.076 2.98(1.53-5.83) 0.001 

Iridodonesis NA NA NA NA NA NA Iris flocculi NA NA NA NA NA NA Joint hypermobility 0.92(0.49-1.73) 0.799 1.30(0.42-4.07) 0.651 0.82(0.38-1.78) 0.617 Kyphosis 2.60(1.20-5.62) 0.015 1.35(0.19-9.68) 0.765 3.29(1.48-7.30) 0.003 Livedo reticularis 0.85(0.22-3.32) 0.82 NA* NA* 1.30(0.35-4.90) 0.696 Low set ears 3.02(1.11-8.24) 0.031 NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 1.25(0.56-2.83) 0.585 0.91(0.21-3.89) 0.898 1.80(0.69-4.67) 0.227 Micrognathia 1.18(0.45-3.10) 0.741 2.39(0.58-9.82) 0.227 0.78(0.20-3.03) 0.717 Missing teeth 3.10(1.38-7.00) 0.006 3.95(0.82-19.15) 0.088 4.38(1.81-10.57) 0.001 Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture 1.58(0.26-9.69) 0.622 NA NA NA NA Pectus carinatum deformity 1.43(0.62-3.25) 0.4 2.11(0.41-10.82) 0.371 1.51(0.58-3.98) 0.4 Pectus excavatum or chest asymmetry 0.86(0.41-1.79) 0.69 1.76(0.62-5.00) 0.291 0.51(0.13-2.05) 0.345 Pes planus 0.77(0.40-1.49) 0.439 0.72(0.22-2.30) 0.578 0.90(0.40-2.02) 0.8 Positive thumb sign NA* NA* NA* NA* NA* NA* Positive wrist sign 0.54(0.14-2.15) 0.38 NA* NA* 1.02(0.27-3.93) 0.972 Reduced elbow extension NA NA NA NA NA NA Retinal detachment* 4.02(1.50-10.76) 0.006 1.70(0.24-11.83) 0.592 2.03(0.55-7.44) 0.285 Retrognathia 0.91(0.37-2.23) 0.844 0.89(0.21-3.80) 0.87 1.05(0.34-3.24) 0.925 Scoliosis NA NA NA NA NA NA Skin hyperextensibility 1.72(0.66-4.47) 0.266 NA* NA* 2.07(0.81-5.28) 0.128 Skin striae 0.46(0.15-1.43) 0.179 NA* NA* 0.67(0.17-2.66) 0.572 Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax 1.42(0.38-5.33) 0.602 1.68(0.25-11.43) 0.595 1.40(0.23-8.69) 0.715 Teeth crowding 2.06(0.93-4.56) 0.075 1.81(0.39-8.29) 0.447 3.00(1.24-7.27) 0.015 Thin or transluscent skin* 2.41(1.41-4.12) 0.001 2.78(1.06-7.31) 0.038 2.05(1.08-3.90) 0.029 Tortuosity of intracranial arteries 0.61(0.19-1.89) 0.388 NA* NA* 0.59(0.15-2.33) 0.448 Tortuosity of the aorta 1.99(1.04-3.80) 0.038 1.85(0.63-5.46) 0.265 2.36(1.07-5.21) 0.034 Tortuosity of the vertebral or carotid arteries 1.30(0.70-2.43) 0.409 3.75(1.14-12.29) 0.029 0.85(0.37-1.99) 0.714 Wide or atrophic scars 3.25(1.84-5.73) <0.001 2.24(0.76-6.58) 0.144 4.29(2.25-8.17) <0.001   *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.      

Supplemental Table 16. Phenotypic and systemic risk factor in TGFBR1 participants. Systemic and cardiovascular risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia NA NA NA NA NA NA Atrial fibrillation NA NA NA NA NA NA Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 1.94(0.72-5.25) 0.228 1.53(0.28-8.48) 0.624 2.29(0.68—7.72) 0.183 Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 0.95(0.23-3.98) 0.949 1.15(0.14-9.36) 0.899 0.89(0.12-6.37) 0.906 Phenotypic risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot NA NA NA NA NA NA Craniosynostosis NA NA NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA* NA* NA NA NA NA Digital abnormalities NA* NA* NA NA NA NA Dolichocephaly NA* NA* NA NA NA* NA* Doughy skin texture 1.84(0.66-5.15) 0.248 NA NA 1.71(0.49-5.95) 0.402 Downslanting palpebral fissures NA* NA* NA NA NA NA Ectopia lentis NA NA NA NA NA NA Emphysema NA NA NA NA NA NA Enophthalmos NA NA NA NA NA NA Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia NA* NA* NA NA NA NA High arched palate 0.65(0.16-2.72) 0.556 NA* NA* 1.00(0.23-4.31) 1 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA NA NA NA NA NA Hypertelorism* 1.51(0.51-4.47) 0.460 0.91(0.11-7.51) 0.931 1.94(0.54-6.92) 0.308 Iridodonesis NA NA NA NA NA NA 

Iris flocculi NA NA NA NA NA NA Joint hypermobility 1.02(0.34-3.07) 0.972 1.55(0.25-9.42) 0.637 0.81(0.19-3.54) 0.779 Kyphosis NA NA NA NA NA NA Livedo reticularis NA* NA* NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia NA* NA* NA* NA* 0.86(0.12-5.94) 0.876 Micrognathia NA* NA* NA NA NA NA Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity NA* NA* NA NA NA* NA* Pectus excavatum or chest asymmetry 0.80(0.19-3.32) 0.758 3.00(0.49-18.31) 0.234 NA* NA* Pes planus 0.53(0.15-1.80) 0.306 NA* NA* 0.57(0.13-2.55) 0.466 Positive thumb sign NA* NA* NA NA NA NA Positive wrist sign 0.83(0.12-5.63) 0.844 NA NA 0.98(0.14-6.61) 0.98 Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA* NA* NA NA NA NA Retrognathia 1.21(0.19-7.88) 0.84 NA NA 1.00(0.15-6.77) 1 Scoliosis NA NA NA NA NA NA Skin hyperextensibility NA* NA* NA NA NA* NA* Skin striae NA* NA* NA NA NA NA Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax NA NA NA NA NA NA Teeth crowding NA* NA* NA NA NA NA Thin or transluscent skin* 2.46(0.92-6.58) 0.072 2.33(0.43-12.62) 0.325 2.41(0.70-8.24) 0.161 Tortuosity of intracranial arteries NA* NA* NA NA NA* NA* Tortuosity of the aorta 1.20(0.30-4.82) 0.797 1.56(0.19-12.51) 0.678 1.05(0.15-7.10) 0.962 Tortuosity of the vertebral or carotid arteries 1.14(0.39-3.28) 0.81 NA* NA* NA* NA* Wide or atrophic scars 1.89(0.58-6.15) 0.288 NA* NA* 3.89(1.17-12.91) 0.026  *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.        

Supplemental Table 17. Phenotypic and systemic risk factor in TGFBR2 participants. Systemic and cardiovascular risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia 1.80(0.24-13.30) 0.565 NA NA NA NA Atrial fibrillation 1.74(0.24-12.87) 0.586 NA NA NA NA Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 2.78(1.03-7.51) 0.044 1.38(0.2-7.08) 0.699 4.65(1.20-18.01) 0.026 Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 1.70(0.51-5.68) 0.389 2.73(0.55-13.62) 0.220 1.04(0.14-14.06) 0.970 Phenotypic risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot 3.80(0.96-14.95) 0.057 NA NA NA NA Craniosynostosis NA* NA* NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA NA NA NA NA NA Digital abnormalities 6.62(1.88-23.26) 0.003 11.67(1.24-109.46) 0.031 4.86(0.98-24.19) 0.054 Dolichocephaly 1.58(0.36-6.97) 0.546 8.00(0.80-79.66) 0.076 NA* NA* Doughy skin texture 8.64(1.86-40.07) 0.006 6.89(0.70-67.55) 0.098 10.25(1.24-84.87) 0.031 Downslanting palpebral fissures 1.88(0.41-8.56) 0.413 6.15(0.61-62.46) 0.124 NA NA Ectopia lentis NA NA NA NA NA NA Emphysema NA NA NA NA NA NA Enophthalmos 1.67(0.24-11.76) 0.606 2.29(0.27-19.04) 0.445 NA NA Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia NA* NA* NA NA NA NA High arched palate 3.86(0.97-15.26) 0.054 3.50(0.34-36.22) 0.293 4.60(0.85-24.97) 0.077 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA NA NA NA NA NA Hypertelorism* 5.68(1.85-17.40) 0.002 4.93(0.76-32.10) 0.095 6.08(1.51-24.57) 0.011 Iridodonesis NA NA NA NA NA NA 

Iris flocculi NA NA NA NA NA NA Joint hypermobility 1.91(0.51-7.15) 0.337 3.29(0.33-32.99) 0.312 1.40(0.26-7.71) 0.697 Kyphosis 2.97(0.71-12.43) 0.136 3.36(0.35-32.34) 0.295 NA NA Livedo reticularis NA NA NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 1.21(0.16-9.05) 0.85 2.20(0.22-21.95) 0.502 NA NA Micrognathia NA NA NA NA NA NA Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity 9.73(1.96-48.40) 0.005 NA* NA* 8.33(1.61-43.07) 0.011 Pectus excavatum or chest asymmetry 1.54(0.46-5.12) 0.484 3.21(0.35-29.12) 0.299 1.32(0.18-9.93) 0.784 Pes planus 1.27(0.34-4.76) 0.727 5.83(0.65-52.16) 0.115 NA* NA* Positive thumb sign 1.83(0.25-13.40) 0.55 NA NA NA NA Positive wrist sign 1.43(0.19-10.73) 0.726 NA NA 1.82(0.24-14.06) 0.565 Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA* NA* NA NA NA NA Retrognathia NA* NA* 1.65(0.16-16.81) 0.671 NA* NA* Scoliosis NA NA NA NA NA NA Skin hyperextensibility NA NA NA NA NA NA Skin striae 3.15(0.72-13.77) 0.127 4.17(0.44-39.38) 0.213 NA NA Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax 4.11(1.07-15.82) 0.040 NA NA NA NA Teeth crowding 6.00(1.56-23.03) 0.009 NA NA 5.78(1.19-27.97) 0.029 Thin or transluscent skin* 3.41(1.09-10.64) 0.034 3.42(0.52-22.69) 0.203 3.23(0.78-13.44) 0.107 Tortuosity of intracranial arteries NA* NA* NA* NA* NA* NA* Tortuosity of the aorta 2.43(0.69-8.53) 0.166 1.45(0.17-12.69) 0.735 3.86(0.86-17.35) 0.078 Tortuosity of the vertebral or carotid arteries 0.98(0.25-3.91) 0.979 NA* NA* 1.19(0.24-5.95) 0.828 Wide or atrophic scars 3.70(1.18-11.66) 0.025 6.00(0.93-38.63) 0.059 2.80(0.62-12.72) 0.182  *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.        

Supplemental Table 18. Phenotypic and systemic risk factor in SMAD3 participants.  Systemic and cardiovascular risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia 2.13(0.57-7.96) 0.262 NA NA NA NA Atrial fibrillation 1.17(0.29-4.74) 0.829 NA NA 1.07(0.15-7.62) 0.945 Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 4.60(1.89-11.24) 0.001 NA* NA* 2.89(1.01-8.25) 0.047 Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 5.47(2.26-13.25) <0.001 NA* NA* 3.17(1.09-9.23) 0.035 Phenotypic risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot NA NA NA NA NA NA Craniosynostosis NA NA NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA NA NA NA NA NA Digital abnormalities NA* NA* NA NA NA NA Dolichocephaly NA NA NA NA NA NA Doughy skin texture 2.95(1.09-7.98) 0.033 NA NA 3.18(1.04-9.70) 0.042 Downslanting palpebral fissures 3.28(1.16-9.29) 0.025 NA NA 4.29(1.42-12.97) 0.01 Ectopia lentis NA NA NA NA NA NA Emphysema NA NA NA NA NA NA Enophthalmos NA NA NA NA NA NA Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia 0.98(0.14-6.87) 0.986 NA* NA* 1.70(0.26-11.07) 0.580 High arched palate 2.37(0.91-6.20) 0.077 2.15(0.42-10.91) 0.357 2.57(0.78-8.47) 0.121 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA NA NA NA NA NA Hypertelorism* 3.21(1.07-9.67) 0.038 NA NA 2.22(0.57-8.63) 0.249 

Iridodonesis NA NA NA NA NA NA Iris flocculi NA NA NA NA NA NA Joint hypermobility 1.30(0.39-4.31) 0.662 NA NA 1.58(0.46-5.43) 0.467 Kyphosis 1.49(0.23-9.61) 0.677 NA NA NA NA Livedo reticularis NA NA NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 2.04(0.55-7.51) 0.284 NA NA NA NA Micrognathia 2.97(0.84-10.48) 0.091 NA NA 2.87(0.78-10.61) 0.113 Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity 2.58(0.74-9.01) 0.136 NA NA NA NA Pectus excavatum or chest asymmetry NA* NA* NA* NA* NA NA Pes planus 0.99(0.29-3.34) 0.99 NA* NA* 2.32(0.70-7.74) 0.17 Positive thumb sign NA NA NA NA NA NA Positive wrist sign NA NA NA NA NA NA Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA NA NA NA NA NA Retrognathia NA NA NA NA NA NA Scoliosis NA NA NA NA NA NA Skin hyperextensibility NA NA NA NA NA NA Skin striae NA* NA* NA* NA* NA NA Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax NA NA NA NA NA NA Teeth crowding 2.14(0.57-8.02) 0.261 1.75(0.19-16.15) 0.622 NA NA Thin or transluscent skin* 1.95(0.73-5.17) 0.180 1.85(0.23-14.95) 0.564 1.77(0.58-5.38) 0.314 Tortuosity of intracranial arteries 1.21(0.18-8.04) 0.84 NA NA 1.24(0.19-8.21) 0.823 Tortuosity of the aorta 2.28(0.81-6.40) 0.116 3.75(0.74-19.02) 0.111 1.70(0.42-6.89) 0.458 Tortuosity of the vertebral or carotid arteries 1.69(0.43-6.65) 0.456 NA NA 1.60(0.40-6.48) 0.51 Wide or atrophic scars 4.62(1.77-12.01) 0.002 3.21(0.42-24.37) 0.260 5.72 (2.07-15.79) 0.001  *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.      

Supplemental Table 19. Phenotypic and systemic risk factor in TGFB2 participants. Systemic and cardiovascular risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia NA* NA* NA NA NA NA Atrial fibrillation 1.07(0.14-8.09) 0.95 NA* NA* NA NA Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 0.78(0.16-3.69) 0.92 NA* NA* NA* NA* Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 3.82(1.02-14.33) 0.047 5.47(0.53-56.95) 0.155 4.07(0.70-21.10) 0.094 Phenotypic Risk factors  Overall Male Female Risk factor RR (95% CI) p value RR (95% CI) Risk factor Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot NA NA NA NA NA NA Craniosynostosis NA NA NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA NA NA NA NA NA Digital abnormalities NA* NA* NA NA NA NA Dolichocephaly 1.45(0.19-11.33) 0.72 NA* NA* NA NA Doughy skin texture 2.26(0.49-10.48) 0.298 NA* NA* 1.62(0.30-8.67) 0.573 Downslanting palpebral fissures 3.26(0.71-15.07) 0.13 NA* NA* 2.89(0.56-14.83) 0.204 Ectopia lentis NA NA NA NA NA NA Emphysema NA NA NA NA NA NA Enophthalmos 2.27(0.30-17.18) 0.426 NA NA 1.83(0.24-13.80) 0.556 Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia NA* NA* NA NA NA NA High arched palate 1.23(0.24-6.38) 0.803 NA* NA* 1.14(0.14-9.02) 0.902 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA* NA* NA* NA* NA* NA* Hypertelorism* NA NA NA NA NA NA Iridodonesis NA NA NA NA NA NA 

Iris flocculi NA NA NA NA NA NA Joint hypermobility NA* NA* NA* NA* NA* NA* Kyphosis 7.67(1.74-33.78) 0.007 NA NA NA NA Livedo reticularis 1.96(0.26-14.96) 0.518 NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 2.66(0.53-13.30) 0.235 NA* NA* 1.83(0.24-13.80) 0.556 Micrognathia 1.09(0.14-8.60) 0.938 NA* NA* NA* NA* Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity NA* NA* 1.00(0.52-1.94) 1 NA NA Pectus excavatum or chest asymmetry 1.64(0.32-8.43) 0.554 NA* NA* NA* NA* Pes planus 0.64(0.12-3.35) 0.598 NA* NA* 1.03(0.19-5.65) 0.97 Positive thumb sign NA* NA* NA* NA* NA NA Positive wrist sign NA* NA* NA* NA* NA NA Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA NA NA NA NA NA Retrognathia 1.44(0.28-7.42) 0.661 NA* NA* 1.14(0.14-9.02) 0.902 Scoliosis NA NA NA NA NA NA Skin hyperextensibility NA* NA* NA NA NA NA Skin striae NA* NA* NA* NA* 0.89(0.11-7.14) 0.91 Smooth philtrum NA NA NA NA NA NA Spontaneous pneumothorax NA NA NA NA NA NA Teeth crowding 2.75(0.35-21.37) 0.333 NA NA NA NA Thin or transluscent skin* 2.35 (0.56-9.91) 0.245 5.89 (0.40-85.91) 0.195 1.30(0.24-7.20) 0.763 Tortuosity of intracranial arteries 4.40(1.01-19.17) 0.048 NA NA NA NA Tortuosity of the aorta 1.81(0.24-13.46) 0.560 NA* NA* NA NA Tortuosity of the vertebral or carotid arteries 2.34(0.56-9.74) 0.241 NA* NA* 1.14(0.14-9.02) 0.902 Wide or atrophic scars 5.02(1.23-20.38) 0.024 4.64(0.31-68.59) 0.264 NA NA *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.         

Supplemental Table 20. Phenotypic and systemic risk factor in FBN1 participants. Systemic and cardiovascular risk factors  Overall Male Female Risk Factor RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value Arrhythmia 1.00(0.44-2.27) 1 NA NA NA NA Atrial fibrillation NA NA NA NA NA NA Congestive heart failure NA NA NA NA NA NA Deep vein thrombosis NA NA NA NA NA NA Diabetes NA NA NA NA NA NA Hyperlipidemia NA NA NA NA NA NA Hypertension* 3.30(1.09-10.03) 0.035 5.91(1.86-18.76) 0.003 NA* NA* Hyperthyroidism NA NA NA NA NA NA Idiopathic cardiomyopathy NA NA NA NA NA NA Myocardial infarction NA NA NA NA NA NA Smoking* 2.45(0.81-7.38) 0.112 3.29(1.04-10.35) 0.042 NA* NA* Phenotypic features  Overall Male Female Risk Factor RR (95% CI) p value RR (95% CI) Abnormal uvula NA NA NA NA NA NA Bowel rupture NA NA NA NA NA NA Cleft palate NA NA NA NA NA NA Club foot NA* NA* NA NA NA NA Craniosynostosis NA NA NA NA NA NA Crumpled ears NA NA NA NA NA NA Decreased subcutaneous fat NA NA NA NA NA NA Digital abnormalities NA* NA* NA* NA* 1.00(0.49-2.02) 1 Dolichocephaly 6.14(0.43-87.32) 0.180 NA NA NA NA Doughy skin texture NA NA NA NA NA NA Downslanting palpebral fissures NA* NA* NA* NA* 1.00(0.49-2.05) 1 Ectopia lentis NA* NA* NA NA 1.00(0.41-2.45) 1 Emphysema NA NA NA NA NA NA Enophthalmos 2.64(0.18-39.43) 0.481 2.00(0.15-27.45 0.604 1.00(0.43-2.33) 1 Hemoptysis requiring hospitalization NA NA NA NA NA NA Hernia 1.50(0.20-11.08) 0.688 2.27(0.31-16.51) 0.419 NA* NA* High arched palate NA* NA* NA* NA* 1.00(0.49-2.03) 1 Hip deformity  Protrusio acetabulae  NA NA NA NA NA NA Hyperextensibility of knee NA* NA* NA NA 1.00(0.41-2.45) 1 Hypertelorism* NA* NA* NA* NA* NA* NA* Iridodonesis NA NA NA NA NA NA 

Iris flocculi NA NA NA NA NA NA Joint hypermobility NA* NA* NA NA 1.00(0.41-2.45) 1 Kyphosis NA* NA* NA NA NA NA Livedo reticularis NA NA NA NA NA NA Low set ears NA NA NA NA NA NA Lung bullae  blebs   NA NA NA NA NA NA Malar hypoplasia 8.33(0.60-116.70) 0.115 NA NA NA NA Micrognathia NA NA NA NA NA NA Missing teeth NA NA NA NA NA NA Muscle atrophy in legs or arms NA NA NA NA NA NA Muscle contracture NA NA NA NA NA NA Pectus carinatum deformity NA NA NA NA NA NA Pectus excavatum or chest asymmetry NA* NA* NA* NA* 1.00(0.49-2.03) 1 Pes planus NA* NA* NA NA 1.00(0.49-2.05) 1 Positive thumb sign 1.00(0.59-1.71) 1 1.00(0.44-2.27) 1 1.00(0.49-2.02) 1 Positive wrist sign 1.00(0.57-1.74) 1 1.00(0.39-2.45) 1 1.00(0.49-2.03) 1 Reduced elbow extension NA NA NA NA NA NA Retinal detachment* NA* NA* NA* NA* NA* NA* Retrognathia NA* NA* NA* NA* 1.00(0.43-2.32) 1 Scoliosis NA NA NA NA NA NA Skin hyperextensibility NA NA NA NA NA NA Skin striae 4.18(0.28-61.77) 0.298 1.89(0.13-26.78) 0.638 NA NA Smooth philtrum NA* NA* NA* NA* NA NA Spontaneous pneumothorax NA NA NA NA NA NA Teeth crowding NA NA NA NA NA NA Thin or transluscent skin* 9.13(1.40-59.78) 0.021 NA NA NA NA Tortuosity of intracranial arteries NA NA NA NA NA NA Tortuosity of the aorta NA NA NA NA NA NA Tortuosity of the vertebral or carotid arteries NA NA NA NA NA NA Wide or atrophic scars NA NA NA NA NA NA  *Data from French cohort available NA: Not available to calculate  NA*: Not available, excluded according to predefined criteria.        

Supplemental Figure 1:Time-to event for arterial events, direct comparison with COL3A1.  
  (A) Time-to-event analysis for arterial events comparing COL3A1 (red) with other genes. Early onset of arterial events in COL3A1 are observed when compared with  TGFBR1 carriers (A), TGFBR2 (B), SMAD3 (C), TGFB2 (D) and FBN1 (E). The cumulative probability of arterial events is plotted as a function of age (years), and the number of individuals at risk is provided below each graph. All p-values were calculated using the log-rank test.                       


Supplemental Figure 2:Time-to event for arterial events, comparation between LDS genes.
   (A) Time-to-event analysis for arterial events comparing LDS invidivually does not show any statisticall significance among the comparations TGFBR1 vs TGFBR2 carriers (A), TGFBR1 vs TGFB2 (B), TGFBR1 vs SMAD3 (C), TGFBR2 vs TGFB2 (D), TGFBR2 vs SMAD3 (E) and TGFB2 vs SMAD3 (F). The cumulative probability of arterial events is plotted as a function of age (years), and the number of individuals at risk is provided below each graph. All p-values were calculated using the log-rank test.                      


Supplemental Figure 3:Time-to event for arterial events, direct comparation with FBN1.  
 Time-to-event analysis for arterial events comparing FBN1 (red) with other genes. Significative early onset of arterial events compared to all the genes. The cumulative probability of arterial events is plotted as a function of age (years), and the number of individuals at risk is provided below each graph. All p-values were calculated using the log-rank test.                       


Supplemental Figure 4:Time-to event for arterial events, direct comparison with COL3A1, in males.  
 Kaplan-Meier survival curves depict the time to first arterial event in males with COL3A1 (red) compared with other genes (blue). In all comparisons, COL3A1 carriers experienced significantly earlier arterial events. (A) COL3A1 vs. TGFBR1 (p = 0.003), (B) COL3A1 vs. TGFBR2 (p < 0.001), (C) COL3A1 vs. SMAD3 (p < 0.001), (D) COL3A1 vs. TGFB2 (p < 0.001), (F) and COL3A1 vs FBN1 (p < 0.001) The cumulative probability of arterial events is plotted as a function of age (years), with the number of individuals at risk provided below each graph. P-values were calculated using log-rank test                      


Supplemental Figure 5:Time-to event for arterial events, direct comparison with COL3A1, in females.  
  Kaplan-Meier survival curves depict the time to first arterial event in female with COL3A1 (red) compared with carriers of other gene variants (blue). In most of comparisons, there was no significant difference in arterial event timing between COL3A1 and the other genes. (A) COL3A1 vs. TGFBR1 (p = 0.32), (B) COL3A1 vs. TGFBR2 (p = 0.203), (C) COL3A1 vs. SMAD3 (p = 0.11), and (D) COL3A1 vs. TGFB2 (p = 0.228). While shows differences for COL3A1 vs FBN1 (p<0.001). The cumulative probability of arterial events is plotted as a function of age (years), with the number of individuals at risk provided below each graph. P-values were calculated using log-rank tests.                     


Supplemental Figure 6: Total arterial events localization per zone, breakdown by sex and type of arterial event.  
 These heatmaps illustrates the distribution of arterial events across anatomical zones, stratified by gene variant and sex (overall: left; females: middle; males: right). Event percentages are represented by color intensity, with darker shades indicating higher frequencies. Panel (A) displays the distribution of all arterial events, while panels (B), (C), and (D) represent events categorized as dissections, ruptures, and repairs, respectively. The data provides insights into the anatomical and genetic patterns associated with arterial pathology. 


Supplemental Figure 7. Heatmaps of arterial events distribution by artery, breakdown by sex, and type of arterial event.  
 These heatmaps illustrates the distribution of arterial events across specific artery, stratified by gene variant and sex (overall: left; females: middle; males: right). Event percentages are represented by color intensity, with darker shades indicating higher frequencies. Panel (A) displays the distribution of all arterial events, while panels (B), (C), and (D) represent events categorized as dissections, ruptures, and repairs, respectively. The data provides insights into the anatomical and genetic patterns associated with arterial pathology. 


   Supplemental Figure 8: Time to aortic event all genes. 
  Kaplan-Meier survival curves demonstrate the time to the first aortic event across multiple gene variants, including COL3A1, TGFBR1, TGFBR2, SMAD3, TGFB2, and FBN1. TGFBR2 (yellow line) has the earliest onset of aortic events compared to other gene variants, as indicated by the earlier rise in the cumulative probability curve. The cumulative probability of aortic events is plotted as a function of age (in years), with each gene represented by a different colored line. P-values for the comparison between these gene variants were calculated using log-rank tests.   


Supplemental Figure 9: Kaplan-Meier curves for aortic events by gene with TGFBR2 as reference.  
 Kaplan-Meier survival curves compare the time to first aortic event in TGFBR2 carriers (blue) against other genes (red). (A) TGFBR2 vs. COL3A1 shows a significantly earlier onset of events in TGFBR2 carriers (p < 0.001). (B) TGFBR2 vs. TGFBR1 demonstrates a significant difference with TGFBR2 carriers experiencing earlier events (p = 0.016). (C) TGFBR2 vs. SMAD3 also shows a highly significant difference, with earlier events in TGFBR2 carriers (p < 0.001). (D) TGFBR2 vs. TGFB2 highlights a significant difference in event timing, favoring TGFBR2 (p < 0.001). (E) TGFBR2 vs. FBN1 shows a statistically significant difference (p < 0.001). The cumulative probability of aortic events is plotted as a function of age (years), and the number of individuals at risk is listed below each graph. P-values were calculated using log-rank tests.    


Supplemental Figure 10: Kaplan-Meier curves for aortic events by gene multiple comparations. 
 Kaplan-Meier survival curves compare the time to first aortic event among individual LDS genes, FBN1 an the cumulative of LDS and FBN1. Comparations between COL3A1 and TGFBR1 (A), SMAD3 (B), TGFB2 (C), FBN1 (D), TGFBR1 and TGFB2 (E), SMAD3 (F), FBN1 (G), TGFB2 and SMAD3 (H), FBN1 (I), SMAD3 and FBN1 (J), and TGFB pathway genes and FBN1 (K). The cumulative probability of aortic events is plotted as a function of age (years), and the number of individuals at risk is listed below each graph. P-values were calculated using log-rank tests.        


 Supplemental Figure 11: Arterial and aortic events in males.  
 Kaplan-Meier survival curves show the cumulative probability of aortic (red) and arterial events (blue) in males with different gene variants. (A) COL3A1 does not show a significant difference between aortic and arterial events (p = 0.691). (B) TGFBR1, (C) TGFBR2, (D) SMAD3, (E) TGFB2, and (F) FBN1 all show significantly earlier aortic events compared to arterial events (p < 0.001 for each). The cumulative probability of events is plotted by age, with the number of individuals at risk shown below each graph. P-values were calculated using log-rank tests.                           


 Supplemental figure 12: Arterial and aortic events, female.   
 Kaplan-Meier survival curves depict the cumulative probability of aortic events (red) and arterial events (blue) in females with different gene variants. (A) COL3A1 shows no significant difference between aortic and arterial events (p = 0.948). (B) TGFBR1 shows difference (p = 0.013). (C) TGFBR2 exhibits a significantly earlier onset of aortic events compared to arterial events (p < 0.001). (D) SMAD3 display a significantly earlier onset of aortic events compared to arterial events (p = 0.001). (E) TGFB2 shows no significant difference between aortic and arterial events (p = 0.375). (F) FBN1 shows significant differences with early aortic events (p <0.001) The cumulative probability of events is plotted as a function of age (years), and the number of individuals at risk for both aortic and arterial events is provided below each graph. P-values were calculated using log-rank tests.     


Supplemental Figure 13: Incidence Rate Events by Gene and By Decade per 1000 Person Years (100 people over 1 decade)  
    Incidence rate of arterial events across decades for six genes: COL3A1, TGFBR1, TGFBR2, SMAD3, TGFB2, and FBN1. The x-axis represents age in decades, while the y-axis represents the incidence rate per 1000 person-years. (B) Incidence rate of aortic events across decades for the same six genes, with axes and scales matching those in panel (A). 


 Supplemental Information 1. Modification of classifying pathogenic or likely pathogenic (P/LP) variants We modified the following criteria based on the ClinGen General Sequence Variant Curation Process Standard Operating Procedure v3.2 (https://clinicalgenome.org/site/assets/files/7438/variant_curation_sop_v3_2_oct_2022.pdf).  PS4 The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. For variants with minor allele frequency (MAF) < 0.00001 in gnomAD v2.1.1. PS4:   5 or more probands carry the same variant. PS4 moderate:  3 or 4 probands carry the same variant. PS4 supporting: 3 or 4 probands carry the same variant.  PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation PM1 strong: FBN1 variants alter Cysteine residues in cbEGF-like domains PM1:  FBN1 variants alter Cysteine residues in EGF-like domains, TB domain, or hybrid  domain. (D/N)-X-(D/N)-(E/Q)-Xm-(D/N)-Xn-(Y/F) substitution in cbEGF-like domain, invariant calcium-binding or hydroxylation residue in cbEGF-like domain, critical Gly between Cys2-Cys3 in cbEGF-like domain, Gly between Cys3-Cys4 if there is an upstream cbEGF domain, Cys-creating variants. PM1: COL3A1 variants alter critical Glycine residues (G-X-Y) at COL3A1 triple helix region.    PM2 Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM2 supporting: MAF < 0.00001 in gnomAD v2.1.1.  PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease. PP1_suporting: 2 affected individuals from the same family carry the variant.  PP1_moderate:   3-4 affected individuals from the same family carry the variant. PP1_strong:   5 or more affected individuals from the same family carry the variant.  PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product. We modified this rule based on REVEL scores suggested by a paper (PMID: 36413997) PP3 supporting: 0.644 ≤ REVEL score < 0.773 PP3 moderate:  0.773 ≤ REVEL score < 0.932 PP3 supporting: REVEL score ≥ 0.932  